Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Q1 2026 earnings

Reported May 12, 2026 · After market close

Diluted EPS-$0.22Miss by $0.04
EPS estimate-$0.18

Next report

Aug 6, 2026 (In 3 weeks)
EPS estimate-$0.21

Financials

Q1 2026

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$683.47M+8,046%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Current ratio18.3×+13.0×

Versus estimates

Diluted EPS

Q1 2026-$0.22Miss by $0.04
Q4 2025-$0.27Miss by $0.13Q3 2025-$0.30Miss by $0.26Q2 2025-$0.30Miss by $0.05Q1 2025-$0.58Miss by $0.27Q4 2024-$0.62Beat by $0.08

Ask the moment Relmada Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Relmada Therapeutics, Inc. report Q1 2026 earnings?
Relmada Therapeutics, Inc. (RLMD) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Relmada Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Relmada Therapeutics, Inc. reported diluted EPS of $-0.22 for Q1 2026.
Did Relmada Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.18 by $0.04.
How did Relmada Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 62.1% from $-0.58.
Where can I find Relmada Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-055164) and the 10-Q periodic report (0001213900-26-055059) directly on SEC EDGAR. The filing index links above go to sec.gov.